Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. (SHE:301584)
China · Delayed Price · Currency is CNY 22.25
-0.70 (-3.05%)
At close: Jul 21, 2026
SHE:301584 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 19,393 | 19,386 | 17,882 | 30,857 | 23,749 | 10,008 |
Other Revenue | 44.14 | 44.14 | 40.4 | -15,414 | -11,867 | 16.39 |
| 19,437 | 19,430 | 17,923 | 15,443 | 11,882 | 10,024 | |
Revenue Growth (YoY) | 7.64% | 8.41% | 16.05% | 29.97% | 18.54% | 17.35% |
Cost of Revenue | 17,950 | 17,944 | 16,602 | 14,264 | 10,986 | 9,339 |
Gross Profit | 1,487 | 1,486 | 1,321 | 1,179 | 896.48 | 685.03 |
Selling, General & Admin | 800.09 | 802.34 | 711.33 | 674.83 | 513.09 | 390.28 |
Research & Development | 28.73 | 27.43 | 26.02 | 30.62 | 13.62 | 4.79 |
Other Operating Expenses | 34.01 | 33.71 | 27.11 | 21.8 | 15.52 | 14.12 |
Operating Expenses | 899.29 | 906.23 | 778.86 | 736.54 | 573.42 | 423.58 |
Operating Income | 587.37 | 579.63 | 541.74 | 442.8 | 323.06 | 261.45 |
Interest Expense | -119.7 | -132.27 | -162.01 | -132.88 | -77.99 | -38.35 |
Interest & Investment Income | 6.4 | 7.37 | 8.42 | 7.79 | 6.44 | 7.25 |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | 1.52 | 1.15 | -0.77 | -0.23 |
Other Non Operating Income (Expenses) | -6.7 | -9.01 | -7.56 | -0.58 | -3.9 | -0.33 |
EBT Excluding Unusual Items | 467.32 | 445.67 | 382.11 | 318.28 | 246.85 | 229.79 |
Gain (Loss) on Sale of Investments | -10.23 | -8.1 | -12.44 | -6.5 | -3.04 | -1.72 |
Gain (Loss) on Sale of Assets | 1.84 | 2.12 | 0.89 | 0.23 | 0.33 | -0.03 |
Asset Writedown | 14.83 | 0.06 | 0 | -0.28 | - | -0.04 |
Other Unusual Items | 11.77 | 11.77 | 7.31 | 3.44 | 5.15 | 3.01 |
Pretax Income | 485.53 | 451.52 | 377.87 | 315.18 | 249.29 | 231.01 |
Income Tax Expense | 126.31 | 116.37 | 104.08 | 88.31 | 60.07 | 55.25 |
Earnings From Continuing Operations | 359.22 | 335.15 | 273.79 | 226.88 | 189.22 | 175.76 |
Minority Interest in Earnings | -73.63 | -65.51 | -45.48 | -30.57 | -14.94 | -8.82 |
Net Income | 285.6 | 269.63 | 228.31 | 196.3 | 174.28 | 166.94 |
Net Income to Common | 285.6 | 269.63 | 228.31 | 196.3 | 174.28 | 166.94 |
Net Income Growth | 24.50% | 18.10% | 16.30% | 12.64% | 4.40% | 4.55% |
Shares Outstanding (Basic) | 395 | 374 | 357 | 357 | 356 | 355 |
Shares Outstanding (Diluted) | 401 | 380 | 357 | 357 | 356 | 355 |
Shares Change (YoY) | 12.67% | 6.46% | -0.05% | 0.35% | 0.14% | 0.10% |
EPS (Basic) | 0.72 | 0.72 | 0.64 | 0.55 | 0.49 | 0.47 |
EPS (Diluted) | 0.71 | 0.71 | 0.64 | 0.55 | 0.49 | 0.47 |
EPS Growth | 10.50% | 10.94% | 16.36% | 12.25% | 4.25% | 4.44% |
Free Cash Flow | 947.04 | 667.6 | 43.42 | -456.96 | -661.39 | -743.15 |
Free Cash Flow Per Share | 2.37 | 1.76 | 0.12 | -1.28 | -1.86 | -2.09 |
Dividend Per Share | 0.200 | 0.200 | - | - | - | - |
Gross Margin | 7.65% | 7.65% | 7.37% | 7.64% | 7.54% | 6.83% |
Operating Margin | 3.02% | 2.98% | 3.02% | 2.87% | 2.72% | 2.61% |
Profit Margin | 1.47% | 1.39% | 1.27% | 1.27% | 1.47% | 1.67% |
Free Cash Flow Margin | 4.87% | 3.44% | 0.24% | -2.96% | -5.57% | -7.41% |
EBITDA | 629.8 | 619.88 | 573.24 | 457.4 | 328.66 | 265.85 |
EBITDA Margin | 3.24% | 3.19% | 3.20% | 2.96% | 2.77% | 2.65% |
D&A For EBITDA | 42.43 | 40.25 | 31.5 | 14.59 | 5.61 | 4.39 |
EBIT | 587.37 | 579.63 | 541.74 | 442.8 | 323.06 | 261.45 |
EBIT Margin | 3.02% | 2.98% | 3.02% | 2.87% | 2.72% | 2.61% |
Effective Tax Rate | 26.01% | 25.77% | 27.54% | 28.02% | 24.09% | 23.92% |
Revenue as Reported | 19,437 | 19,430 | 17,923 | 15,443 | 11,882 | 10,024 |
Advertising Expenses | - | 9.24 | 1.49 | 1.41 | 0.63 | 0.71 |